We have located links that may give you full text access.
Gastrointestinal microbiota disruption and risk of colonization with carbapenem-resistant Pseudomonas aeruginosa in ICU patients.
Clinical Infectious Diseases 2018 November 2
Background: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) can colonize the gastrointestinal (GI) tract of intensive care unit (ICU) patients and CRPA colonization puts patients at increased risk of CRPA infection. Prior studies have not examined relationships between the microbiota, medications, and CRPA colonization-acquisition.
Methods: Data and peri-rectal swabs were obtained from a cohort of ICU patients at the University of Maryland Medical Center. Patients (N=109) were classified into three groups by CRPA colonization-acquisition status and antimicrobial exposure. We conducted 16S rRNA gene sequencing of an ICU admission swab and ≥ one additional swab and evaluated associations between patient characteristics, medications, the GI microbiota, and CRPA colonization-acquisition.
Results: ICU patients had low levels of diversity and high relative abundance of pathobionts. Piperacillin-tazobactam was prescribed more frequently to patients with CRPA colonization-acquisition than those without. Piperacillin-tazobactam was associated with low abundance of potentially protective taxa (e.g., Lactobacillus and Clostridiales) and increased risk of Enterococcus domination [odds ratio (OR) 5.50; 95% confidence interval (CI) (2.03-14.92)]. Opioids were associated with dysbiosis in patients who did not receive antibiotics; potentially protective Blautia and Lactobacillus were higher in patients who did not receive opioids. A group of correlated taxa, identified at ICU admission, were associated with lower risk of CRPA colonization-acquisition [OR 0.58; 95% CI (0.38-0.87)].
Conclusions: Antibiotics differed in their impact on the microbiota with piperacillin-tazobactam being particularly damaging. Certain bacterial taxa (e.g., Clostridiales) were negatively associated with CRPA colonization-acquisition. These taxa may be markers of risk for CRPA colonization-acquisition and/or serve a protective role.
Methods: Data and peri-rectal swabs were obtained from a cohort of ICU patients at the University of Maryland Medical Center. Patients (N=109) were classified into three groups by CRPA colonization-acquisition status and antimicrobial exposure. We conducted 16S rRNA gene sequencing of an ICU admission swab and ≥ one additional swab and evaluated associations between patient characteristics, medications, the GI microbiota, and CRPA colonization-acquisition.
Results: ICU patients had low levels of diversity and high relative abundance of pathobionts. Piperacillin-tazobactam was prescribed more frequently to patients with CRPA colonization-acquisition than those without. Piperacillin-tazobactam was associated with low abundance of potentially protective taxa (e.g., Lactobacillus and Clostridiales) and increased risk of Enterococcus domination [odds ratio (OR) 5.50; 95% confidence interval (CI) (2.03-14.92)]. Opioids were associated with dysbiosis in patients who did not receive antibiotics; potentially protective Blautia and Lactobacillus were higher in patients who did not receive opioids. A group of correlated taxa, identified at ICU admission, were associated with lower risk of CRPA colonization-acquisition [OR 0.58; 95% CI (0.38-0.87)].
Conclusions: Antibiotics differed in their impact on the microbiota with piperacillin-tazobactam being particularly damaging. Certain bacterial taxa (e.g., Clostridiales) were negatively associated with CRPA colonization-acquisition. These taxa may be markers of risk for CRPA colonization-acquisition and/or serve a protective role.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app